- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 September 2025 | 65 | GlobeNewswire (Europe) | Third quarter (July-September 2025)
Operating loss amounted to SEK 146,689 (-2,697,267).
Loss for the period amounted to SEK 304,153 (-2,514,629).
Cash flow from operating activities totaled SEK... ► Artikel lesen | |
| 13.11. | Elicera Therapeutics announces that the Swedish Cancer Society has awarded Professor Magnus Essand at Uppsala University a grant of 7.5 million SEK for CAR T-cell research | 1 | Cision News | ||
| 23.10. | Elicera Therapeutics AB (publ) changes Certified Adviser and Liquidity provider to DNB Carnegie Investment Bank AB (publ) | 2 | Cision News | ||
| 19.09. | ELICERA THERAPEUTICS: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 2 | Cision News | ||
| 19.09. | Elicera Therapeutics AB: Elicera clarifies status of the iTANK-platform patent application in the U.S. | 151 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| ELICERA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 29.08. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 30 June 2025 | 180 | GlobeNewswire (Europe) | Second quarter (April-June 2025)
Operating loss amounted to SEK -2,892,341 (-5,841,409).
Loss for the period amounted to SEK -2,732,070 (-5,622,779).
Cash flow from operating activities totaled... ► Artikel lesen | |
| 25.08. | ELICERA THERAPEUTICS: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 2 | Cision News | ||
| 25.08. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in four out of six patients in the first two low dose cohorts of the CARMA study with iTANK-armed CAR T-cell therapy | 140 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 25.08. | Elicera Therapeutics AB: Elicera Therapeutics Continues Phase I/IIa CARMA Study with CAR T-Cell Therapy as Planned Following Safety Committee's Assessment in Cohort 2 | 150 | GlobeNewswire (Europe) | Gothenburg, August 25, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 28.05. | Elicera Therapeutics AB: Elicera Therapeutics enters a Material Transfer Agreement with University Hospital Tübingen for testing of the company's oncolytic virus candidates, ELC-100 and ELC-201 | 191 | GlobeNewswire (Europe) | Gothenburg, May 28, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on its proprietary commercial technology... ► Artikel lesen | |
| 22.05. | Elicera Therapeutics AB: Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy | 188 | GlobeNewswire (Europe) | Gothenburg, May 22, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 15.05. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Interim 1 January - 31 March 2025 | 186 | GlobeNewswire (Europe) | First quarter (January-March 2025)
Operating loss amounted to SEK -8,069,404 (-5,433,422).
Loss for the period amounted to SEK -8,013,462 (-5,369,677).
Cash flow from operating activities totalled... ► Artikel lesen | |
| 10.04. | Elicera Therapeutics AB: Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee's assessment of cohort 1 | 357 | GlobeNewswire (Europe) | Gothenburg, April 10, 2025 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies... ► Artikel lesen | |
| 26.02. | Elicera Therapeutics - Positioned to deliver in cell and gene therapies | 394 | Edison Investment Research | Elicera Therapeutics is a cell and gene therapy company utilising its iTANK platform to develop immunotherapies for solid and bloodborne tumours. Its pipeline comprises two CAR-T therapies and two oncolytic... ► Artikel lesen | |
| 03.02. | Elicera Therapeutics AB: Elicera Therapeutics AB (publ) Year-end Report 1 January - 31 December 2024 | 184 | GlobeNewswire (Europe) | Fourth quarter (October-December 2024)
Operating profit/loss amounted to SEK -2,911,958 (-5,212,694).
Loss for the period amounted to SEK -2,603,242 (-4,749,222).
Cash flow from operating activities... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 5,226 | -0,27 % | Aktien KW 49 Doch noch? Jahresendrallye auf den letzten Drücker? News. Aurubis.Bilfinger. Hochtief. Strabag. Jost. Evotec. Mutares. Tonies. NAGA. 2G Energy. Hausvorteil. Procredit. artec Technologies | Aktien: Diese Woche setzte sich letztendlich nach Rückschlägen die Erholung fort. Am Freitag schaffte der DAX sogar die 24.000er Marke wieder. Eigentlich zu spät für eine Jahresendrallye. Vor allem:... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 625,40 | -0,98 % | Regeneron Reports Promising Phase 1/2 Data Of Lynozyfic In Newly Diagnosed Multiple Myeloma | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging results from the Phase 1/2 LINKER-MM4 trial evaluating Lynozyfic (linvoseltamab) in adults with newly diagnosed... ► Artikel lesen | |
| BRAIN BIOTECH | 3,030 | +0,66 % | Der Erfolg von Pharvaris freut Brain Biotech | ||
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| CARDIOL THERAPEUTICS | 0,911 | +1,56 % | Cardiol Therapeutics Inc.: New Data from the Phase II ARCHER Trial Demonstrate CardiolRx Improves Heart Structure in Patients with Acute Myocarditis, Supporting Expansion Across Inflammatory Cardiac Conditions | Phase II ARCHER trial showed a significant reduction in left ventricular (LV) mass (p=0.0117) and improvements in multiple key cardiac MRI (CMR) measures of structural heart recovery in patients with... ► Artikel lesen | |
| BURCON NUTRASCIENCE | 1,000 | -6,54 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2026 Second Quarter Results | Vancouver, British Columbia--(Newsfile Corp. - November 12, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen | |
| CSL | 103,96 | +0,29 % | CSL LIMITED: Update - Notification of buy-back - CSL | ||
| MANNKIND | 5,024 | -0,79 % | MannKind: Leerink hebt Kursziel wegen Tyvaso-DPI-Lizenzeinnahmen auf 9 US-Dollar an | ||
| OXFORD NANOPORE TECHNOLOGIES | 1,442 | -2,04 % | Oxford Nanopore Technologies: Appointment of Francis Van Parys as Chief Executive Officer | Oxford Nanopore Technologies, the company delivering a new generation of molecular sensing technology based on nanopores, today announces the appointment of Francis Van Parys as Chief Executive Officer... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 12,465 | +0,44 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Plans to Accelerate NDA Submission Timeline for AXPAXLI in Wet AMD | Ocular intends to submit AXPAXLI New Drug Application (NDA) for wet AMD shortly after year one data from SOL-1, if positive SOL-1 topline data remain on track for 1Q 2026 Ocular plans to leverage... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,055 | 0,00 % | Adaptimmune Therapeutics PLC: Adaptimmune Announces Changes to Board and Executive Leadership Team | Philadelphia, Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - November 17, 2025) - Adaptimmune Therapeutics plc (OTC Pink: ADAPY) ("Adaptimmune" or the "Company") today announced changes... ► Artikel lesen | |
| CODEXIS | 1,451 | +1,68 % | Codexis, Inc.: Codexis Reports Third Quarter 2025 Financial Results | Announces signing of $37.8m Supply Assurance Agreement with Merck Organizational changes streamline company and reduce operational expenses Cash runway extended through 2027 REDWOOD CITY, Calif.,... ► Artikel lesen | |
| CORMEDIX | 10,100 | +3,06 % | CRMD Up More Than 40% YTD: Time to Buy, Sell or Hold the Stock? | ||
| TELO GENOMICS | 0,033 | 0,00 % | Telo Genomics Corp.: Telo Genomics Presents Genomic Profiles of Peripheral Blood Minimal Residual Disease Cells at the 67th American Society of Hematology Meeting | Toronto, Ontario--(Newsfile Corp. - December 11, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for... ► Artikel lesen | |
| ALIGOS THERAPEUTICS | 11,100 | -1,77 % | Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
Das Unternehmen ELICERA THERAPEUTICS AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,003 (-0,58 %) liegt der Kurs bei 0,516 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELICERA THERAPEUTICS AB finden Sie auf Wallstreet Online.